AL-1095

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
AL-1095
AL-1095 Structure.svg
Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: unscheduled
Identifiers
  • 2-(1-phenyl-1-(p-chlorophenyl)methyl)-3-hydroxyquinuclidine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H22ClNO
Molar mass327.85 g·mol−1
3D model (JSmol)
  • OC(C1CCN2CC1)C2C(C3=CC=C(Cl)C=C3)C4=CC=CC=C4
  • InChI=1S/C20H22ClNO/c21-17-8-6-15(7-9-17)18(14-4-2-1-3-5-14)19-20(23)16-10-12-22(19)13-11-16/h1-9,16,18-20,23H,10-13H2/t18?,19-,20+/m0/s1 checkY
  • Key:JXCMZYHEZWCLOD-NRRUETGQSA-N checkY
 ☒NcheckY (what is this?)  (verify)

AL-1095,[1] developed by Aldrich[citation needed], is a centrally acting stimulant drug with comparable effects to amphetamine,[2] developed by Bristol in the 1970s.[3]

See also[edit]

References[edit]

  1. ^ US 3506673, Warawa ED, Mueller NJ, "2-(4'Halo)-Benzhydryl-3-Quinuclidinols", issued 14 April 1970, assigned to Aldrich Chemical Company 
  2. ^ Hedblom P, Grinspoon L (1975). The Speed Culture: Amphetamine Use and Abuse in America. Cambridge: Harvard University Press. p. 50. ISBN 0-674-83192-6.
  3. ^ Warawa EJ, Mueller NJ (January 1975). "Quinuclidine Chemistry. 3. β-cis-2-(4'-Chlorobenzhydryl)-3-quinuclidinol, a New Central Nervous System Stimulant. Importance of the Benzhydryl Configuration". Journal of Medicinal Chemistry. 18 (1): 71–4. doi:10.1021/jm00235a016. PMID 803245.